This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Heron Therapeutics, Inc., San Diego, CA. USA.
Reference
Burns D, et al. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis. Advances in Therapy : 23 May 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01377-z
Rights and permissions
About this article
Cite this article
Use of aprepitant for chemotherapy-induced nausea/vomiting saves cost. PharmacoEcon Outcomes News 855, 29 (2020). https://doi.org/10.1007/s40274-020-6894-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6894-2